Polymorphic carbazole derivatives and uses thereof
By providing a pharmaceutical composition of compound A and its polymorphic forms, AHR is directly inhibited, solving the problems of immunosuppression and tumor promotion caused by AHR activation in the prior art, and achieving therapeutic and research effects on related diseases.
CN122404338APending Publication Date: 2026-07-17IKENA ONCOLOGY INC
View PDF 31 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- IKENA ONCOLOGY INC
- Filing Date
- 2020-11-25
- Publication Date
- 2026-07-17
AI Technical Summary
Technical Problem
The lack of effective AHR inhibitors in current technologies means that the immunosuppression and tumor-promoting effects caused by AHR activation cannot be effectively treated.
Method used
Provides compound A and its polymorphic forms and pharmaceutically acceptable compositions for the direct inhibition of AHR, including the free base form and salt form of compound A, administered in various physical forms such as solutions, suspensions or solids to treat the associated disease.
Benefits of technology
Compound A and its compositions can effectively inhibit AHR, reduce the severity of related diseases, study the biological and pathological phenomena of AHR, and be used for in vitro and in vivo evaluation of AHR inhibitors.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN122404338A_ABST
Abstract
本申请涉及多晶型咔唑衍生物及其用途。本发明提供了游离碱和盐形式及其组合物和方法，可用于通过施用充当芳烃受体(AHR)抑制剂的小分子治疗剂来治疗其中涉及AHR的各种症状。
Need to check novelty before this filing date? Find Prior Art